Ethical and economic considerations of rare diseases in ethnic minorities: The case of mucopolysaccharidosis VI in Colombia

Journal of Medical Ethics

Volumn 38, Issue 11, 2012, Pages 699-700

  Rosselli, Diego ^a   Rueda, Juan David ^b   Solano, Martha ^a  

^a PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^b FUNDACIÓN CARDIOINFANTIL INSTITUTO DE CARDIOLOGÍA   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

N ACETYLGALACTOSAMINE 4 SULFATASE;

ARTICLE; COLOMBIA; DISABLED PERSON; ECONOMICS; ENZYME REPLACEMENT; ENZYMOLOGY; ETHNIC GROUP; ETHNOLOGY; HUMAN; MAROTEAUX LAMY SYNDROME; MINORITY GROUP; RARE DISEASE;

COLOMBIA; DISABLED PERSONS; ENZYME REPLACEMENT THERAPY; ETHNIC GROUPS; HUMANS; MINORITY GROUPS; MUCOPOLYSACCHARIDOSIS VI; N-ACETYLGALACTOSAMINE-4-SULFATASE; RARE DISEASES;

EID: 84870350793     PISSN: 03066800     EISSN: 14734257     Source Type: Journal    
DOI: 10.1136/medethics-2011-100204     Document Type: Article

References (18)

1. Trachtenberg EA, Keyeux G, Bernal JE, et al. Results of Expedicion Humana. I. Analysis of HLA class II (DRB1-DQA1-DPB1) alleles and DR-DQ haplotypes in nine Amerindian populations from Colombia. Tissue Antigens 1996;48:174-81.
2. Baehner F, Schmiedeskamp C, Krummenauer F, et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 2005;28:1011-17.
3. Malm G, Lund AM, Månsson JE, et al. Mucopolysaccharidoses in the Scandinavian countries: incidence and prevalence. Acta Paediatr 2008;97:1577-81.
4. Miles KA, Packer C, Stevens A. Quantifying emerging drugs for very rare conditions. QJM 2007;100:291-5.
5. Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI. Pediatrics 2007;120:405-18.
6. Auclair D, Hopwood JJ, Brooks DA, et al. Replacement therapy in mucopolysaccharidosis type VI: advantages of early onset of therapy. Mol Genet Metab 2003;78:163-74.
7. Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 2006;148:533-9.
8. Harmatz P. Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Inherit Metab Dis 2010;33:51-60.
9. Decker C, Giugliani R, Schwartz IV, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Pediatr Rehabil Med 2010;3:89-100.
10. Schlander M, Beck M. Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI. Curr Med Res Opin 2009;25:1285-93.
11. Bernal J, Briceño I, Duncan R. El arte del chamanismo, la salud y la vida, Tumaco-La Tolita. Bogotá: Instituto Colombiano de Cultura Hispánica, 1993.
12. Rodríguez CA, Pachajoa H. Salud y enfermedad en el arte prehispánico de la cultura Tumaco-La Tolita. Cali: Editorial Universidad del Valle, 2010.
13. Bernal JE, Briceno I. Genetic and other diseases in the pottery of Tumaco-la Tolita culture in Colombia-Ecuador. Clin Genet 2006;70:188-91.
14. Sánchez E, Arango R. Los pueblos indígenas de Colombia en el umbral del nuevo milenio. Bogota: Departamento Nacional de Planeación, 2004. http://www.dnp.gov. co (accessed 4 Mar 2011).
15. Tambuyzer E. Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nat Rev Drug Discov 2010;9:921e9.
16. Cookson R, McCabe C, Tsuchiya A. Public healthcare resource allocation and the Rule of Rescue. J Med Ethics 2008;34:540e4.
17. Lane E. Chile mine rescue to cost $20m. BBC News. 14 October 2010. http://www.bbc.co.uk/news/business-11541634 (accessed 31 May 2011).
18. Kaback M, Lim-Steele J, Dabholkar D, et al. Tay-Sachs disease-carrier screening, prenatal diagnosis, and the molecular era: an international perspective, 1970 to 1993. JAMA 1993;270:2307-15.